Beyond Bapi: Alzheimer’s Pipeline Runs Deep
Executive Summary
With the failure of the second of four Janssen-led Phase III trials testing bapineuzumab, partners Janssen and Pfizer have elected to discontinue the bapineuzumab I.V. clinical development program. Nonetheless, the anti-amyloid-beta approach is still alive, as the field turns to early, pre-symptomatic intervention.
You may also be interested in...
A Busy Year-End, In Brief: December Brings Slate Of Approvals, And Setbacks
In addition to a spate of FDA approvals closing out the year, Roche contended with trial failures and Actavis received a “complete response” letter for its nebivolol/valsartan combination.
BIO 2014 Monday Round-Up: Let’s Make A Deal
The annual BIO conference opened in San Diego with deals being announced at the outset and everyone enthusiastic about partnering.
Alzheimer’s Placebo May Become Disease-Modifying Drug For Affiris
Biotech shifts development plans after Phase II study shows surprising, but promising, results – albeit in the wrong arm of the study.